Patents by Inventor Erhan I. Altinoglu

Erhan I. Altinoglu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9149544
    Abstract: Non-aggregating resorbable calcium phosphosilicate nanoparticles (CPNPs) are bioconjugated to targeting molecules that are specific for particular cells. The CPNPs are stable particles at normal physiological pH. Chemotherapy and imaging agents may be integrally formed with the CPNPs so that they are compartmentalized within the CPNPs. In this manner, the agents are protected from interaction with the environment at normal physiological pH. However, once the CPNPs have been taken up, at intracellular pH, the CPNPs dissolve releasing the agent. Thus, chemotherapeutic or imaging agents are delivered to specific cells and permit the treatment and/or imaging of those cells. Use of the bioconjugated CPNPs both limits the amount of systemic exposure to the agent and delivers a higher concentration of the agent to the cell. The methods and principals of bioconjugating CPNPs are taught by examples of bioconjugation of targeting molecules for breast cancer, pancreatic cancer, and leukemia.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: October 6, 2015
    Assignee: THE PENN STATE RESEARCH FOUNDATION
    Inventors: Thomas T. Morgan, Brian M. Barth, James H. Adair, Rahul Sharma, Mark Kester, Sriram S. Shanmugavelandy, Jill P. Smith, Erhan I. Altinoglu, Gail L. Matters, James M. Kaiser, Christopher McGovern
  • Patent number: 8771741
    Abstract: Nano-encapsulated photosensitizers and their use in the treatment of tumors and/or imaging is described. Preferably, the photosensitizers are encapsulated in a calcium phosphate nanoparticle (CPNP). Encapsulating the PS in a CPNP increases the half-life of the PS, increases absorption of the PS into the target cell tissue, increases the photostability of the PS, increases the photoefficiency of the PS, increases in vivo retention of the PS, or combinations thereof, ultimately making it a highly efficacious agent for use in photodynamic therapy, imaging target tissues, vessels, or tumors, and/or detecting or locating tumors.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: July 8, 2014
    Assignee: The Penn State Research Foundation
    Inventors: James H. Adair, Mark Kester, Erhan I. Altinoglu, Brian M. Barth, Timothy J. Russin, James M. D. Kaiser, Thomas T. Morgan, Karen L. Eklund
  • Publication number: 20140154325
    Abstract: Nano-encapsulated photosensitizers and their use in the treatment of tumors and/or imaging is described. Preferably, the photosensitizers are encapsulated in a calcium phosphate nanoparticle (CPNP). Encapsulating the PS in a CPNP increases the half-life of the PS, increases absorption of the PS into the target cell tissue, increases the photostability of the PS, increases the photoefficiency of the PS, increases in vivo retention of the PS, or combinations thereof, ultimately making it a highly efficacious agent for use in photodynamic therapy, imaging target tissues, vessels, or tumors, and/or detecting or locating tumors.
    Type: Application
    Filed: February 7, 2014
    Publication date: June 5, 2014
    Applicant: THE PENN STATE RESEARCH FOUNDATION
    Inventors: James H. Adair, Mark Kester, Peter C. Eklund, Erhan I. Altinoglu, Brian M. Barth, Timothy J. Russin, James M.D. Kaiser, Thomas T. Morgan
  • Publication number: 20110129413
    Abstract: Non-aggregating resorbable calcium phosphosilicate nanoparticles (CPNPs) are bioconjugated to targeting molecules that are specific for particular cells. The CPNPs are stable particles at normal physiological pH. Chemotherapy and imaging agents may be integrally formed with the CPNPs so that they are compartmentalized within the CPNPs. In this manner, the agents are protected from interaction with the environment at normal physiological pH. However, once the CPNPs have been taken up, at intracellular pH, the CPNPs dissolve releasing the agent. Thus, chemotherapeutic or imaging agents are delivered to specific cells and permit the treatment and/or imaging of those cells. Use of the bioconjugated CPNPs both limits the amount of systemic exposure to the agent and delivers a higher concentration of the agent to the cell. The methods and principals of bioconjugating CPNPs are taught by examples of bioconjugation of targeting molecules for breast cancer, pancreatic cancer, and leukemia.
    Type: Application
    Filed: November 8, 2010
    Publication date: June 2, 2011
    Inventors: Thomas T. Morgan, Brian M. Barth, James H. Adair, Rahul Sharma, Mark Kester, Sriram S. Shanmugavelandy, Jill P. Smith, Erhan I. Altinoglu, Gail L. Matters, James M. Kaiser, Christopher McGovern